Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

two-drug regime

Gilead Sciences

Gilead gets EU nod for cancer drug Zydelig

Approved for patients with chronic lymphocytic leukaemia and follicular lymphoma

- PMLiVE

Gilead’s simtuzumab fails pancreatic cancer trial

Showed little difference in progression-free survival compared to placebo results

- PMLiVE

Sovaldi deal for developing world ‘falls short’

Critics claim Gilead have allowed Indian companies to set their own price

- PMLiVE

H4B’s charity team launches Catalyst4Change

The comms agency aims to 'help smaller charities be heard'

- PMLiVE

ViiV bags US approval for HIV blockbuster-in-waiting

Drug combines antiretrovirals with Tivicay

- PMLiVE

Merck & Co taps music industry for US HIV campaign

Pharma company to work with music promoter Maria Davis and Positive Women’s Network – USA

- PMLiVE

Celgene’s cancer drug promising in small HIV study

Lymphoma therapy Istodax shows potential in treating the virus

- PMLiVE

Failed HIV cure can’t dent spirit at Melbourne conference

Still 'feasible' to end Aids epidemic by 2030

- PMLiVE

Pharma joins tributes to Aids researchers lost on flight MH17

Toll of Malaysian Airlines jet crash in Ukraine includes 'HIV hero' Dr Joep Lange

The seven letter debate that is Sovaldi

Reimbursement of high cost hepatitis C drugs raise difficult issues

Gilead Sciences

Sovaldi stumbles as NICE assesses hep C drug’s price

Gilead must provide much more cost-effectiveness information

EU flag

Europe extends clinical trial project with African researchers

Partnership has already developed eight improved medical treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links